Amelia Zelnak

4.1k total citations
45 papers, 1.0k citations indexed

About

Amelia Zelnak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Amelia Zelnak has authored 45 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Amelia Zelnak's work include Advanced Breast Cancer Therapies (19 papers), Breast Cancer Treatment Studies (19 papers) and Cancer Treatment and Pharmacology (18 papers). Amelia Zelnak is often cited by papers focused on Advanced Breast Cancer Therapies (19 papers), Breast Cancer Treatment Studies (19 papers) and Cancer Treatment and Pharmacology (18 papers). Amelia Zelnak collaborates with scholars based in United States, Australia and Türkiye. Amelia Zelnak's co-authors include Ruth O’Regan, Paraskevi Giannakakou, Ruth O’Regan, Elisavet Paplomata, Adam I. Marcus, Shala L. Thomas, Tarun M. Kapoor, Sarah Garrett, Ulf Peters and Hyunsuk Shim and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer.

In The Last Decade

Amelia Zelnak

43 papers receiving 989 citations

Peers

Amelia Zelnak

ONCOL

PRM

GENET

Judit Grueso Spain

Cansu Karakaş United States

Jaime Acquaviva United States

Shi Chang United States

Karen G. Montgomery Australia

Babita Saigal United States

Valerie M. Jansen United States

Lesley Mathews United States

Akshara Singareeka Raghavendra United States

Martín A. Rivas Argentina

Judit Grueso Spain

Amelia Zelnak

616 ×1.2

ONCOL

491 ×1.3

PRM

504 ×1.6

184 ×0.6

163 ×1.1

GENET

Citations per year, relative to Amelia Zelnak Amelia Zelnak (= 1×) peers Judit Grueso

Countries citing papers authored by Amelia Zelnak

Since Specialization

Citations

This map shows the geographic impact of Amelia Zelnak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amelia Zelnak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amelia Zelnak more than expected).

Fields of papers citing papers by Amelia Zelnak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amelia Zelnak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amelia Zelnak. The network helps show where Amelia Zelnak may publish in the future.

Co-authorship network of co-authors of Amelia Zelnak

This figure shows the co-authorship network connecting the top 25 collaborators of Amelia Zelnak. A scholar is included among the top collaborators of Amelia Zelnak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amelia Zelnak. Amelia Zelnak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Taylor, Caitlin, Jane Meisel, Aimee J. Foreman, et al.. (2023). Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. 199(1). 91–98. 5 indexed citations

Bardia, Aditya, Sara A. Hurvitz, Angela DeMichele, et al.. (2021). Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clinical Cancer Research. 27(15). 4177–4185. 80 indexed citations

Mueller, Volkmar, Erika Hamilton, Amelia Zelnak, et al.. (2020). 275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM). Annals of Oncology. 31. S349–S350. 4 indexed citations

Paplomata, Elisavet, Amelia Zelnak, Cesar A. Santa‐Maria, et al.. (2019). Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. Clinical Breast Cancer. 19(3). 188–196. 2 indexed citations

Moulder, Stacy, Denise A. Yardley, Gail S. Wright, et al.. (2018). Abstract CT107: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Efficacy and safety results from phase II of the TRINITI-1 study. Cancer Research. 78(13_Supplement). CT107–CT107. 3 indexed citations

Davis, Christine, et al.. (2016). Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab. Annals of Pharmacotherapy. 50(9). 712–717. 11 indexed citations

Kandula, Shravan, Jeffrey M. Switchenko, Carolina E. Fasola, et al.. (2015). Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy. International Journal of Breast Cancer. 2015. 1–7. 1 indexed citations

Jegadeesh, N., Sun‐Jin Kim, Roshan S. Prabhu, et al.. (2014). The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients. Annals of Surgical Oncology. 22(4). 1088–1094. 24 indexed citations

Zelnak, Amelia, Petros Nikolinakos, Yuan Liu, et al.. (2014). High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy. Clinical Breast Cancer. 15(1). 31–36. 14 indexed citations

10.

Zelnak, Amelia, Toncred M. Styblo, Monica Rizzo, et al.. (2013). Final Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2-Negative Breast Cancers. Clinical Breast Cancer. 13(3). 173–179. 4 indexed citations

11.

Paplomata, Elisavet, Amelia Zelnak, & Ruth O’Regan. (2013). Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Research and Treatment. 140(3). 453–462. 78 indexed citations

12.

Marcus, David M., Jeffrey M. Switchenko, Roshan S. Prabhu, et al.. (2013). Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer. Frontiers in Oncology. 3. 317–317. 4 indexed citations

13.

Andiç, Fundagül, Karen D. Godette, Ruth O’Regan, et al.. (2011). Treatment adherence and outcome in women with inflammatory breast cancer. Cancer. 117(24). 5485–5492. 13 indexed citations

14.

Lund, Mary Jo, Marina Mošunjac, Kelly M. Davis, et al.. (2011). 21‐Gene recurrence scores. Cancer. 118(3). 788–796. 58 indexed citations

15.

Zelnak, Amelia. (2010). Overcoming Taxane and Anthracycline Resistance. The Breast Journal. 16(3). 309–312. 27 indexed citations

16.

Rizzo, Monica, Harvey L. Bumpers, Joel Okoli, et al.. (2010). Improving on National Quality Indicators of Breast Cancer Care in a Large Public Hospital as a Means to Decrease Disparities for African American Women. Annals of Surgical Oncology. 18(1). 34–39. 10 indexed citations

17.

Zelnak, Amelia & Ruth O’Regan. (2007). Adjuvant Hormonal Therapy for Early-Stage Breast Cancer. Cancer treatment and research. 141. 63–78. 1 indexed citations

18.

Zelnak, Amelia, et al.. (2007). Targeting Angiogenesis in Advanced Breast Cancer. BioDrugs. 21(4). 209–214. 10 indexed citations

19.

Zelnak, Amelia. (2007). Clinical Pharmacology and Use of Microtubule-Targeting Agents in Cancer Therapy. Methods in molecular medicine. 137. 209–234. 13 indexed citations

20.

Zelnak, Amelia & Ruth O’Regan. (2004). Chemoprevention of breast cancer. Current Problems in Cancer. 28(4). 201–217. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact